Flow cytometric analysis of the TME indicated that BTNL2 was primarily expressed on CD45- tumour cells; however, 48.47% of CD45+ leukocytes did also express BTNL2 (Supplementary Fig. 2g). This evidence concerns the gene PTPRC and neoplasm.